No, not the patent-cliff monster Pfizer has become. The Pfizer before it bit off more than it could chew with Wyeth
For instance, Bristol-Myers brought in $895 million this quarter when Eli Lilly
OK, maybe Bristol-Myers is only at mini-Pfizer stage now; before the Wyeth announcement, Pfizer had about $26 billion in cash and equivalents. But Bristol isn't done saving for a rainy day. It'll also get some of the proceeds when it spins off its Mead Johnson Nutrition business in the first half of this year -- a 7% year-over-year increase in revenue last year by the baby formula business should help secure a good price for the IPO.
And of course the company is adding to its cash reserves the old-fashioned way -- by earning it. Bristol-Myers didn't release a cash flow statement with its earnings yesterday -- we'll have to wait for the 10-K -- but the 12 months through September resulted in more than $3 billion in free cash flow. And the company has a plan to increase operating cash flow by $1 billion by the end of next year.
Earnings, which came in up 37% for the year after adjustments, are all fine and dandy, but it's cash that's king and cash is what Fools should be paying attention to. The green stuff pays for the pipeline additions like Bristol-Myers' recent deals with Exelixis
Let's just hope that not getting in a bidding war with Eli Lilly for ImClone is a sign that Bristol-Myers' management is a better value investor than Pfizer's management.
Pfizer is both an Income Investor and an Inside Value selection. Exelixis is a Rule Breakers pick and the Fool owns shares of Pfizer and Exelixis. Try any of our Foolish newsletters today, free for 30 days.
Fool contributor Brian Orelli, Ph.D., would work a pot shot about Pfizer into every article he wrote if his editor would let him. He doesn't own shares of any company mentioned in this article. The Fool's disclosure policy votes for Wi-Phi as the new company name.